PL3313377T3 - Kompozycje i sposoby zastosowania ciałek blaszkowatych do celów terapeutycznych - Google Patents

Kompozycje i sposoby zastosowania ciałek blaszkowatych do celów terapeutycznych

Info

Publication number
PL3313377T3
PL3313377T3 PL16732720T PL16732720T PL3313377T3 PL 3313377 T3 PL3313377 T3 PL 3313377T3 PL 16732720 T PL16732720 T PL 16732720T PL 16732720 T PL16732720 T PL 16732720T PL 3313377 T3 PL3313377 T3 PL 3313377T3
Authority
PL
Poland
Prior art keywords
compositions
methods
therapeutic purposes
lamellar bodies
lamellar
Prior art date
Application number
PL16732720T
Other languages
English (en)
Inventor
Alec MCLEAN
Lynsey HOWARD
Aras KADIOGLU
Craig WINSTANLEY
Original Assignee
Lamellar Biomedical Limited
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lamellar Biomedical Limited filed Critical Lamellar Biomedical Limited
Publication of PL3313377T3 publication Critical patent/PL3313377T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/047—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates having two or more hydroxy groups, e.g. sorbitol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/429—Thiazoles condensed with heterocyclic ring systems
    • A61K31/43—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems
    • A61K31/431—Compounds containing 4-thia-1-azabicyclo [3.2.0] heptane ring systems, i.e. compounds containing a ring system of the formula, e.g. penicillins, penems containing further heterocyclic rings, e.g. ticarcillin, azlocillin, oxacillin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/545—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine
    • A61K31/546—Compounds containing 5-thia-1-azabicyclo [4.2.0] octane ring systems, i.e. compounds containing a ring system of the formula:, e.g. cephalosporins, cefaclor, or cephalexine containing further heterocyclic rings, e.g. cephalothin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/683—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols
    • A61K31/685—Diesters of a phosphorus acid with two hydroxy compounds, e.g. phosphatidylinositols one of the hydroxy compounds having nitrogen atoms, e.g. phosphatidylserine, lecithin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7028—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages
    • A61K31/7034—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin
    • A61K31/7036—Compounds having saccharide radicals attached to non-saccharide compounds by glycosidic linkages attached to a carbocyclic compound, e.g. phloridzin having at least one amino group directly attached to the carbocyclic ring, e.g. streptomycin, gentamycin, amikacin, validamycin, fortimicins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
    • A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/38—Chemical stimulation of growth or activity by addition of chemical compounds which are not essential growth factors; Stimulation of growth by removal of a chemical compound
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dispersion Chemistry (AREA)
  • Communicable Diseases (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cell Biology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Immunology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines Containing Plant Substances (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Cephalosporin Compounds (AREA)
PL16732720T 2015-06-23 2016-06-23 Kompozycje i sposoby zastosowania ciałek blaszkowatych do celów terapeutycznych PL3313377T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1511058.8A GB201511058D0 (en) 2015-06-23 2015-06-23 Compositions and methods for using lamellar bodies for therapeutic purposes
PCT/GB2016/051890 WO2016207645A1 (en) 2015-06-23 2016-06-23 Compositions and methods for using lamellar bodies for therapeutic purposes
EP16732720.4A EP3313377B1 (en) 2015-06-23 2016-06-23 Compositions and methods for using lamellar bodies for therapeutic purposes

Publications (1)

Publication Number Publication Date
PL3313377T3 true PL3313377T3 (pl) 2020-01-31

Family

ID=53784408

Family Applications (1)

Application Number Title Priority Date Filing Date
PL16732720T PL3313377T3 (pl) 2015-06-23 2016-06-23 Kompozycje i sposoby zastosowania ciałek blaszkowatych do celów terapeutycznych

Country Status (24)

Country Link
US (1) US20180169145A1 (pl)
EP (2) EP3313377B1 (pl)
JP (1) JP2018518538A (pl)
KR (1) KR20180036958A (pl)
CN (1) CN107920994A (pl)
AU (1) AU2016281764A1 (pl)
BR (1) BR112017027899A2 (pl)
CA (1) CA2990743A1 (pl)
DK (1) DK3313377T3 (pl)
ES (1) ES2754436T3 (pl)
GB (1) GB201511058D0 (pl)
HK (1) HK1248136A1 (pl)
HR (1) HRP20192091T1 (pl)
HU (1) HUE046510T2 (pl)
IL (1) IL256498A (pl)
LT (1) LT3313377T (pl)
MX (1) MX2018000040A (pl)
PH (1) PH12017502432A1 (pl)
PL (1) PL3313377T3 (pl)
PT (1) PT3313377T (pl)
RS (1) RS59551B1 (pl)
RU (1) RU2017145630A (pl)
WO (1) WO2016207645A1 (pl)
ZA (1) ZA201800372B (pl)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20210145741A1 (en) * 2018-04-17 2021-05-20 Lamellar Biomedical Limited Antifibrotic composition
CN114910325A (zh) * 2022-05-17 2022-08-16 浙江峻山生物科技有限公司 一种人工模拟痰液及其制备方法

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5925375A (en) * 1987-05-22 1999-07-20 The Liposome Company, Inc. Therapeutic use of multilamellar liposomal prostaglandin formulations
US5403592A (en) * 1987-08-25 1995-04-04 Macnaught Pty Limited Lubricant composition for rheumatism
WO1989006686A1 (en) * 1988-01-13 1989-07-27 The Upjohn Company Enhanced production of cellular proteins using butyrate
WO1991012026A1 (en) * 1990-02-14 1991-08-22 Macnaught Pty Limited Means of reducing surgical adhesions
US5741516A (en) * 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5462752A (en) * 1994-07-28 1995-10-31 Prp, Inc. Inhibition of platelet binding
AU7685798A (en) * 1997-05-29 1998-12-30 Applied Biotechnologies Inc. Compositions and methods for preventing adhesion
GB9807298D0 (en) * 1998-04-03 1998-06-03 Britannia Pharmaceuticals Ltd Medicament
CA2319928A1 (en) * 2000-09-18 2002-03-18 Vasogen Ireland Limited Apoptosis-mimicking synthetic entities and use thereof in medical treatments
US8541472B2 (en) * 2001-12-05 2013-09-24 Aseptica, Inc. Antiseptic compositions, methods and systems
US7498292B2 (en) * 2002-08-15 2009-03-03 The Research Foundation Of State University Of New York Combinatorial libraries of autoinducer analogs, autoinducer agonists and antagonists, and methods of use thereof
US7718189B2 (en) * 2002-10-29 2010-05-18 Transave, Inc. Sustained release of antiinfectives
GB0322448D0 (en) * 2003-09-25 2003-10-29 Lamellar Therapeutics Ltd Using lamellar bodies to modify linear biological macro molecules
US7854943B2 (en) * 2004-06-24 2010-12-21 Idexx Laboratories Phospholipid gel compositions for drug delivery and methods of treating conditions using same
CN1634358A (zh) * 2004-11-04 2005-07-06 杨雪 含抗微生物、抗病毒天然精油和磷脂类组合物
ZA200902817B (en) * 2006-10-27 2010-07-28 Athena Biotechnologies Inc Methods of disrupting quorum sensing to affect microbial population cell density
BRPI0806695A2 (pt) * 2007-01-12 2014-06-03 Univ Colorado Composições e métodos para aumentar a tolerância à produção de produtos químicos produzidos por microorganismos
WO2014017233A1 (ja) * 2012-07-27 2014-01-30 住友重機械工業株式会社 微生物用活性調節剤及び微生物の活性を調節する方法

Also Published As

Publication number Publication date
KR20180036958A (ko) 2018-04-10
AU2016281764A1 (en) 2018-01-25
GB201511058D0 (en) 2015-08-05
ES2754436T3 (es) 2020-04-17
HK1248136A1 (zh) 2018-10-12
PT3313377T (pt) 2019-10-31
EP3313377B1 (en) 2019-08-21
CN107920994A (zh) 2018-04-17
WO2016207645A1 (en) 2016-12-29
HRP20192091T1 (hr) 2020-02-21
RU2017145630A3 (pl) 2019-07-24
EP3626232A1 (en) 2020-03-25
CA2990743A1 (en) 2016-12-29
DK3313377T3 (da) 2019-11-11
IL256498A (en) 2018-02-28
RS59551B1 (sr) 2019-12-31
JP2018518538A (ja) 2018-07-12
RU2017145630A (ru) 2019-07-23
ZA201800372B (en) 2020-05-27
US20180169145A1 (en) 2018-06-21
EP3313377A1 (en) 2018-05-02
LT3313377T (lt) 2019-11-25
BR112017027899A2 (pt) 2018-08-28
HUE046510T2 (hu) 2020-03-30
MX2018000040A (es) 2019-01-10
PH12017502432A1 (en) 2018-07-02

Similar Documents

Publication Publication Date Title
HK1257295A1 (zh) 用於免疫腫瘤學的組合物和方法
HK1256225A1 (zh) 寡核苷酸組合物及其方法
HK1255369A1 (zh) 寡核苷酸組合物及其方法
IL258931A (en) Medicinal compounds and methods
GB2546350B (en) Compositions and methods
ZA201805805B (en) Formulations and methods
GB201718876D0 (en) Antithrombin-heparin compositions and methods
HK1252778A1 (zh) 細胞擴增方法和治療組合物
HK1245158A1 (zh) 阿吡莫德組合物及其使用方法
IL255530A (en) Efflux-pump inhibitors and therapeutic uses thereof
ZA201703398B (en) Pharmaceutical composition and methods
HK1250015A1 (zh) 鎮咳藥組合物和方法
GB201705626D0 (en) Compositions and methods
HK1248136A1 (zh) 用於治療目的的板層小體的組合物和方法
ZA201807665B (en) Methods and compositions
IL258431A (en) Deimmunized therapeutic compositions and methods
GB201715820D0 (en) Compositions and methods
GB201512996D0 (en) Compositions and methods
GB201519644D0 (en) Therapy and pharmaceutical composition
ZA201802201B (en) Novel formulation and treatment methods
GB201514413D0 (en) Compositions and methods
ZA201807782B (en) Methods and compositions
IL256261B (en) Hide1 compositions and methods
GB201522554D0 (en) Methods and compositions
GB201521083D0 (en) Compositions for treatment and methods thereof